Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.

Payal Deepak Shah Alexander C Huang George X Xu Robert J Orlowski Ravi K Amaravadi Lynn M Schuchter Paul J Zhang Julia Tchou Tina Matlawski Amanda Cervini Joanne Shea Joan Gilmore Lester Lledo Karen Dengel Amy Marshall E John Wherry Gerald P Linette Andrea Brennan Vanessa E Gonzalez Irina Kulikovskaya Simon F Lacey Gabriela Plesa Carl H June Robert A Anders Tara C Mitchell

Published in: Cancer research communications (2023)

Data evaluating CAR T therapy in patients with solid tumors are limited. This pilot clinical trial demonstrates that intravenous cMET-directed CAR T-cell therapy is safe and feasible in patients with metastatic melanoma and metastatic breast cancer, supporting the continued evaluation of cellular therapy for patients with these malignancies.

Keyphrases

cell therapy
metastatic breast cancer
clinical trial
study protocol
phase ii
phase iii
stem cells
mesenchymal stem cells
open label
randomized controlled trial
electronic health record
high dose
big data
low dose
bone marrow
skin cancer
data analysis